The glycobiology market has been witnessing significant growth due to the increasing prevalence of chronic diseases, such as cancer and autoimmune disorders, which require glycobiology research for the development of effective therapies. The rising demand for personalized medicine and biologics has also been driving the market. The introduction of advanced technologies and techniques, such as mass spectrometry and glycan arrays, has further boosted the market growth. Additionally, the increasing investments in R&D activities and the collaborations between academic and industrial players in the glycobiology field are expected to create lucrative opportunities for market growth. However, the high cost of research and the lack of skilled professionals in the field may hinder market growth. The Asia Pacific region is expected to witness the highest growth due to the increasing investments in healthcare infrastructure and research activities.
Global Glycobiology Market is estimated to be valued at US$ 1,568.73 million in 2022 and is expected to exhibit a CAGR of 12.9% during the forecast period (2022-2030).
Key Players in the Glycobiology Industry:
Tracxn Technologies Limited
Tracxn Technologies Limited is a research and data analytics company founded in 2013, headquartered in Bengaluru, India. The company specializes in tracking startups and private companies across various sectors, including glycobiology. Tracxn provides insights into market trends, investment opportunities, and industry analysis. In 2021, Tracxn launched its Glycobiology Landscape report, which provides an in-depth analysis of the companies, products, and technologies in the glycobiology space.
Agilent Technologies, Inc.
Agilent Technologies, Inc. is a global technology company founded in 1999, headquartered in Santa Clara, California, USA. The company provides analytical instruments, software, services, and consumables for the life sciences, chemical analysis, and diagnostics industries. Agilent's glycobiology solutions include mass spectrometry, capillary electrophoresis, and high-performance liquid chromatography. In 2021, Agilent acquired Resolution Bioscience, a company focused on developing liquid biopsy solutions for cancer diagnostics.
Blirt.eu
Blirt.eu is a biotechnology company founded in 2009, headquartered in Gdansk, Poland. The company specializes in the development of recombinant proteins, antibodies, and enzymes for research and diagnostic purposes. Blirt.eu's glycobiology products include lectins, glycoproteins, and glycosidases. In 2021, the company launched its GlycoEnzyme platform, which enables the production of glycosidases with high activity and specificity.
Takara Bio Inc.
Takara Bio Inc. is a biotechnology company founded in 1967, headquartered in Shiga, Japan. The company develops and sells research reagents, gene editing tools, and diagnostic kits. Takara Bio's glycobiology products include glycosylation enzymes, lectins, and glycobiology kits. In 2021, Takara Bio launched its Glycosylation Master Mix for N-Glycan Profiling, a tool for the analysis of N-glycan structures.
Bio-Techne